Author of

• 25520

  +

  Poster Display session (Friday) (ID 65)

  • Event: ELCC 2018
  • Type: Poster Display session
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1

  • 25304

    +

    82P - Chemotherapy versus combined chemoradiotherapy: Survival patterns among patients with extensive disease small cell lung cancer (ID 283)

    12:30 - 12:30  |  Author(s): M. Hassan
    • Abstract

    Background:
    Extensive Disease Small Cell Lung Cancer (ED-SCLC) represents 30% of lung cancer. While surgery is not an option, chemotherapy is traditionally currently recommended as the standard treatment. As oncologists seek superior modality for better survival, we conducted this study to evaluate the efficacy of combined chemotherapy and thoracic radiotherapy in improving the survival of patients with ED-SCLC, and to identify the characteristics of best candidates.
    
    Methods:
    Using the SEER database, we extracted the data of 5443 patients with ED-SCLC from 2010 to 2013. There were 2665 (49%) patients who underwent combined chemotherapy and thoracic radiotherapy, while 2778 (51%) of them received chemotherapy only. Patients’ demographics and TNM classification were assessed.
    
    Results:
    Patients with ED-SCLC had better outcomes when they received combined chemoradiation, compared with those who received chemotherapy alone, where overall 1-year relative survival rates were 40.2% and 24.1%, respectively (p value <0.001). All patients’ characteristics favor combination over chemotherapy except those aged below 40 years and those over 80 years. Subgroup analysis revealed better survival rates among female patients, patients aged between 40 and 59 years, and those with metastasis to the other lung or free regional lymph nodes. On the other hand, no advantage was allocated to those of specific race or primary site.

    	Survival of Patients
    Variables	Chemoradiation	Chemotherapy	p value
    Sex:
    Male	37.1%	21.5%	<0.001**
    Female	43.9%	27.0%	<0.001**
    Age:
    20–39	28.6%	80.1%	0.914
    40–59	43.3%	25.0%	<0.001**
    60–79	40.0%	24.3%	<0.001**
    ≥80	21.8%	19.6%	0.6
    Race:
    White	39.9%	23.7%	<0.001**
    Black	42.5%	27.7%	0.002**
    Others	40.9%	25.4%	0.002**
    Primary Site:
    Upper Lobe	40.3%	24.3%	<0.001**
    Middle Lobe	47.5%	22.6%	0.001**
    Lower Lobe	38.4%	23.9%	<0.001**
    Overlapping Lesion	44.5%	25.4%	0.01*
    Lymph Nodes Involvement:
    No Nodes Involved	53.6%,	35.5%	<0.001**
    Single Ipsilateral Node	46.8%	31.6%	<0.001**
    Multiple Ipsilateral Nodes	37.5%	22.3%	<0.001**
    Distant Metastasis:
    Lung	37.5%,	21.0%	<0.001**
    Liver	30.2%	19.2%	<0.001**
    Brain	31.5%	22.4%	<0.001**
    Bone	31.6%	21.2%	<0.001**

    
    
    Conclusions:
    Combined chemoradiation in patients with ED-SCLC shows higher 1-year relative survival rates when compared with chemotherapy alone. Further studies should be conducted to weigh the efficacy versus safety to consider using chemoradiation as an alternative modality for ED-SCLC.
    
    Legal entity responsible for the study:
    Inas Uthman
    
    Funding:
    Has not received any funding
    
    Disclosure:
    All authors have declared no conflicts of interest.